Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of May 2026, with a report date of May 19, 2026. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share transactions:
- Instrument: American Depositary Shares (ADS), ISIN: US37733W2044.
- Transaction Price: $49.6700 per ADS.
- Transaction Date: May 15, 2026.
- Exchange: New York Stock Exchange (XNYS).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details routine acquisitions of notional ADS by three executives via dividend reinvestment within the GSK Executive Supplemental Savings Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific share transactions.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of notional ADS resulting from dividend reinvestment, not open market purchases.
- Executives Involved:
- Dr. Hal Barron (Non-Executive Director): 2,300.572 ADS.
- James Ford (SVP and Group General Counsel): 54.387 ADS.
- Maya Martinez-Davis (President, US): 82.387 ADS.
- Share Price Context: The transactions occurred at a uniform price of $49.67 on May 15, 2026.
- Data Limitation: This filing does not contain quarterly or annual financial performance data.